APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Anti-VEGF Drugs for the Treatment of Wet AMD

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Outlook and Growth Opportunities 2026

Report ID 173965490427 December 2025196 pages

Choose your research edition.

Industry ResearchAnti-VEGF Drugs for the Treatment of Wet AMD Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-VEGF Drugs for the Treatment of Wet AMD Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Anti-VEGF Drugs for the Treatment of Wet AMD Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-VEGF Drugs for the Treatment of Wet AMD Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-VEGF Drugs for the Treatment of Wet AMD Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Anti-VEGF Drugs for the Treatment of Wet AMD market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Anti-VEGF Drugs for the Treatment of Wet AMD is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anti-VEGF Drugs for the Treatment of Wet AMD is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-VEGF Drugs for the Treatment of Wet AMD is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Anti-VEGF Drugs for the Treatment of Wet AMD market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Anti-VEGF Drugs for the Treatment of Wet AMD market include Chengdu Kanghong Pharmaceutica, Samsung Bioepis, Roche, Regeneron Pharmaceuticals, Novartis, Coherus BioSciences and Biocon Biologics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Anti-VEGF Drugs for the Treatment of Wet AMD market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anti-VEGF Drugs for the Treatment of Wet AMD and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anti-VEGF Drugs for the Treatment of Wet AMD sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anti-VEGF Drugs for the Treatment of Wet AMD market size, projected growth trends, production technologies, key applications, and end-use industries.

Anti-VEGF Drugs for the Treatment of Wet AMD Segment by Company

Chengdu Kanghong Pharmaceutica

Samsung Bioepis

Roche

Regeneron Pharmaceuticals

Novartis

Coherus BioSciences

Biocon Biologics

Anti-VEGF Drugs for the Treatment of Wet AMD Segment by Type

Single target Drugs

Multi-target Drugs

Anti-VEGF Drugs for the Treatment of Wet AMD Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Anti-VEGF Drugs for the Treatment of Wet AMD Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Anti-VEGF Drugs for the Treatment of Wet AMD status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Anti-VEGF Drugs for the Treatment of Wet AMD market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Anti-VEGF Drugs for the Treatment of Wet AMD significant trends, drivers, influence factors in global and regions.

6. To analyze Anti-VEGF Drugs for the Treatment of Wet AMD competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-VEGF Drugs for the Treatment of Wet AMD market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-VEGF Drugs for the Treatment of Wet AMD and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-VEGF Drugs for the Treatment of Wet AMD.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Anti-VEGF Drugs for the Treatment of Wet AMD market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti-VEGF Drugs for the Treatment of Wet AMD industry.

Chapter 3: Detailed analysis of Anti-VEGF Drugs for the Treatment of Wet AMD manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Anti-VEGF Drugs for the Treatment of Wet AMD in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Anti-VEGF Drugs for the Treatment of Wet AMD in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Anti-VEGF Drugs for the Treatment of Wet AMD Industry Trends Table 2. Anti-VEGF Drugs for the Treatment of Wet AMD Industry Drivers Table 3. Anti-VEGF Drugs for the Treatment of Wet AMD Industry Opportunities and Challenges Table 4. Anti-VEGF Drugs for the Treatment of Wet AMD Industry Restraints Table 5. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Share by Company (2021-2026) Table 7. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume Share by Company (2021-2026) Table 9. Global Anti-VEGF Drugs for the Treatment of Wet AMD Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Anti-VEGF Drugs for the Treatment of Wet AMD Company Ranking, (2024-2026) & (USD Million) Table 11. Global Anti-VEGF Drugs for the Treatment of Wet AMD Key Company Manufacturing Base & Headquarters Table 12. Global Anti-VEGF Drugs for the Treatment of Wet AMD Company, Product Type & Application Table 13. Global Anti-VEGF Drugs for the Treatment of Wet AMD Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Anti-VEGF Drugs for the Treatment of Wet AMD by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Single target Drugs Table 18. Significant Companies of Multi-target Drugs Table 19. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume Share by Type (2021-2026) Table 23. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume Share by Type (2027-2032) Table 24. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type (2021-2026) Table 28. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital and Clinic Table 30. Significant Companies of Retail Pharmacies Table 31. Significant Companies of Other Table 32. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume Share by Application (2021-2026) Table 36. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume Share by Application (2027-2032) Table 37. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application (2021-2026) Table 41. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application (2027-2032) Table 42. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region (2021-2026) & (K Units) Table 44. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Region (2021-2026) Table 45. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region (2027-2032) & (K Units) Table 46. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Region (2027-2032) Table 47. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Region (2021-2026) Table 50. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Region (2027-2032) Table 52. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021-2026) & (K Units) Table 57. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Country (2021-2026) Table 58. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2027-2032) & (K Units) Table 59. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Country (2027-2032) Table 60. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Market Share by Country (2021-2026) Table 62. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Market Share by Country (2027-2032) Table 64. Chengdu Kanghong Pharmaceutica Company Information Table 65. Chengdu Kanghong Pharmaceutica Business Overview Table 66. Chengdu Kanghong Pharmaceutica Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Chengdu Kanghong Pharmaceutica Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio Table 68. Chengdu Kanghong Pharmaceutica Recent Development Table 69. Samsung Bioepis Company Information Table 70. Samsung Bioepis Business Overview Table 71. Samsung Bioepis Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Samsung Bioepis Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio Table 73. Samsung Bioepis Recent Development Table 74. Roche Company Information Table 75. Roche Business Overview Table 76. Roche Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Roche Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio Table 78. Roche Recent Development Table 79. Regeneron Pharmaceuticals Company Information Table 80. Regeneron Pharmaceuticals Business Overview Table 81. Regeneron Pharmaceuticals Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Regeneron Pharmaceuticals Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio Table 83. Regeneron Pharmaceuticals Recent Development Table 84. Novartis Company Information Table 85. Novartis Business Overview Table 86. Novartis Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Novartis Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio Table 88. Novartis Recent Development Table 89. Coherus BioSciences Company Information Table 90. Coherus BioSciences Business Overview Table 91. Coherus BioSciences Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Coherus BioSciences Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio Table 93. Coherus BioSciences Recent Development Table 94. Biocon Biologics Company Information Table 95. Biocon Biologics Business Overview Table 96. Biocon Biologics Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Biocon Biologics Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio Table 98. Biocon Biologics Recent Development Table 99. Key Raw Materials Table 100. Raw Materials Key Suppliers Table 101. Anti-VEGF Drugs for the Treatment of Wet AMD Distributors List Table 102. Anti-VEGF Drugs for the Treatment of Wet AMD Customers List Table 103. Research Programs/Design for This Report Table 104. Authors List of This Report Table 105. Secondary Sources Table 106. Primary Sources List of Figures Figure 1. Anti-VEGF Drugs for the Treatment of Wet AMD Product Image Figure 2. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value (2021-2032) & (US$ Million) Figure 4. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales (2021-2032) & (K Units) Figure 5. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Anti-VEGF Drugs for the Treatment of Wet AMD Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Single target Drugs Image Figure 10. Multi-target Drugs Image Figure 11. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume Share by Type (2021-2032) Figure 14. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type (2021-2032) Figure 17. Hospital and Clinic Image Figure 18. Retail Pharmacies Image Figure 19. Other Image Figure 20. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume Share by Application (2021-2032) Figure 23. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application (2021-2032) Figure 26. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value (2021-2032) & (US$ Million) Figure 31. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value (2021-2032) & (US$ Million) Figure 37. South America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Anti-VEGF Drugs for the Treatment of Wet AMD Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Anti-VEGF Drugs for the Treatment of Wet AMD Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Single target Drugs
  • Multi-target Drugs
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Chengdu Kanghong Pharmaceutica
  • Samsung Bioepis
  • Roche
  • Regeneron Pharmaceuticals
  • Novartis
  • Coherus BioSciences
  • Biocon Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value (2021-2032)
  4. 1.2.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume (2021-2032)
  5. 1.2.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Anti-VEGF Drugs for the Treatment of Wet AMD Market Dynamics
  1. 2.1 Anti-VEGF Drugs for the Treatment of Wet AMD Industry Trends
  2. 2.2 Anti-VEGF Drugs for the Treatment of Wet AMD Industry Drivers
  3. 2.3 Anti-VEGF Drugs for the Treatment of Wet AMD Industry Opportunities and Challenges
  4. 2.4 Anti-VEGF Drugs for the Treatment of Wet AMD Industry Restraints
3 Anti-VEGF Drugs for the Treatment of Wet AMD Market by Company
  1. 3.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Company Revenue Ranking in 2025
  2. 3.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Company (2021-2026)
  3. 3.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume by Company (2021-2026)
  4. 3.4 Global Anti-VEGF Drugs for the Treatment of Wet AMD Average Price by Company (2021-2026)
  5. 3.5 Global Anti-VEGF Drugs for the Treatment of Wet AMD Company Ranking (2024-2026)
  6. 3.6 Global Anti-VEGF Drugs for the Treatment of Wet AMD Company Manufacturing Base and Headquarters
  7. 3.7 Global Anti-VEGF Drugs for the Treatment of Wet AMD Company Product Type and Application
  8. 3.8 Global Anti-VEGF Drugs for the Treatment of Wet AMD Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Anti-VEGF Drugs for the Treatment of Wet AMD Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Anti-VEGF Drugs for the Treatment of Wet AMD Market by Type
  1. 4.1 Anti-VEGF Drugs for the Treatment of Wet AMD Type Introduction
  2. 4.1.1 Single target Drugs
  3. 4.1.2 Multi-target Drugs
  4. 4.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume by Type
  5. 4.2.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Type
  9. 4.3.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Type (2021-2032)
  11. 4.3.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type (2021-2032)
5 Anti-VEGF Drugs for the Treatment of Wet AMD Market by Application
  1. 5.1 Anti-VEGF Drugs for the Treatment of Wet AMD Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Other
  5. 5.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume by Application
  6. 5.2.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Application
  10. 5.3.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Application (2021-2032)
  12. 5.3.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application (2021-2032)
6 Anti-VEGF Drugs for the Treatment of Wet AMD Regional Sales and Value Analysis
  1. 6.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region (2021-2032)
  3. 6.2.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region: 2021-2026
  4. 6.2.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region (2027-2032)
  5. 6.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Region (2021-2032)
  7. 6.4.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Region: 2021-2026
  8. 6.4.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Region (2027-2032)
  9. 6.5 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value (2021-2032)
  12. 6.6.2 North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value (2021-2032)
  15. 6.7.2 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value (2021-2032)
  21. 6.9.2 South America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Country, 2025 VS 2032
7 Anti-VEGF Drugs for the Treatment of Wet AMD Country-level Sales and Value Analysis
  1. 7.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021-2032)
  4. 7.3.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021-2026)
  5. 7.3.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2027-2032)
  6. 7.4 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Country (2021-2032)
  7. 7.4.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Country (2021-2026)
  8. 7.4.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Anti-VEGF Drugs for the Treatment of Wet AMD Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Chengdu Kanghong Pharmaceutica
  2. 8.1.1 Chengdu Kanghong Pharmaceutica Company Information
  3. 8.1.2 Chengdu Kanghong Pharmaceutica Business Overview
  4. 8.1.3 Chengdu Kanghong Pharmaceutica Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Chengdu Kanghong Pharmaceutica Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
  6. 8.1.5 Chengdu Kanghong Pharmaceutica Recent Developments
  7. 8.2 Samsung Bioepis
  8. 8.2.1 Samsung Bioepis Company Information
  9. 8.2.2 Samsung Bioepis Business Overview
  10. 8.2.3 Samsung Bioepis Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Samsung Bioepis Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
  12. 8.2.5 Samsung Bioepis Recent Developments
  13. 8.3 Roche
  14. 8.3.1 Roche Company Information
  15. 8.3.2 Roche Business Overview
  16. 8.3.3 Roche Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Roche Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
  18. 8.3.5 Roche Recent Developments
  19. 8.4 Regeneron Pharmaceuticals
  20. 8.4.1 Regeneron Pharmaceuticals Company Information
  21. 8.4.2 Regeneron Pharmaceuticals Business Overview
  22. 8.4.3 Regeneron Pharmaceuticals Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Regeneron Pharmaceuticals Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
  24. 8.4.5 Regeneron Pharmaceuticals Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Coherus BioSciences
  32. 8.6.1 Coherus BioSciences Company Information
  33. 8.6.2 Coherus BioSciences Business Overview
  34. 8.6.3 Coherus BioSciences Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Coherus BioSciences Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
  36. 8.6.5 Coherus BioSciences Recent Developments
  37. 8.7 Biocon Biologics
  38. 8.7.1 Biocon Biologics Company Information
  39. 8.7.2 Biocon Biologics Business Overview
  40. 8.7.3 Biocon Biologics Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Biocon Biologics Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
  42. 8.7.5 Biocon Biologics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Anti-VEGF Drugs for the Treatment of Wet AMD Value Chain Analysis
  2. 9.1.1 Anti-VEGF Drugs for the Treatment of Wet AMD Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Anti-VEGF Drugs for the Treatment of Wet AMD Sales Mode & Process
  6. 9.2 Anti-VEGF Drugs for the Treatment of Wet AMD Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Anti-VEGF Drugs for the Treatment of Wet AMD Distributors
  9. 9.2.3 Anti-VEGF Drugs for the Treatment of Wet AMD Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst